Second cancer frequently diagnosed in men; prostate cancer is responsible for high mortality. His prognosis has benefited from significant technical improvements. Determining prognostic factors in prostate cancer is an integral part of the therapeutic decision-making process. The aim of this study was to determine the prognostic factors of prostate cancer in the cancer department of University Hospital of Brazzaville in Congo. This was a retrospective descriptive study, which took place from 1 January 2016 to 31 December 2020, in the cancer department of the University Hospital of Brazzaville in Congo. During the study period, 118 files were retained. The survival curves were realized according to the Kaplan-Meier model, and the statistical comparison according to the Log-Rank model. The significance threshold was set at 5%. The results found that mean age was 68 ± 7.74 years. Low urinary tract symptoms accounted for 68.64% of the discovery circumstances. The Initial PSA was greater than 100 ng/ml in 65.25% of patients. Metastases were found in 95.76% of patients. Overall survival at 3 years was 15%. Survival differed significantly by age (p = 0.0017); WHO performance status (p = 0.0000); clinical stage (p = 0.0000) and metastatic site (p = 0.0022). Finally, the incidence of prostate cancer is increasing worldwide, hence the interest of defining a screening strategy, allowing to institute management with better results.
| Published in | International Journal of Clinical Oncology and Cancer Research (Volume 8, Issue 4) |
| DOI | 10.11648/j.ijcocr.20230804.13 |
| Page(s) | 94-100 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2024. Published by Science Publishing Group |
Prostate Cancer, Prognostic Factors, Brazzaville
| [1] | Hyuna S, Jacques F, Rebecca L, Siegel M, Mathieu L, Soerjomataram I, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J CLIN. juin 2021; 71: 206-49. |
| [2] | Tengue K, Kpatcha T, Botcho G, Leloua E, Amavi A, Sikpa K, et al. Profil épidémiologique, diagnostique, thérapeutique et évolutif du cancer de la prostate au Togo. Afr J Urol. 3 juin 2016; 22 (2): 76-82. |
| [3] | Hounnasso P, Avakoudjo J, Aouagbe Behanzin H. Aspects diagnostiques du cancer de la prostate dans le service d’urologie du CNHU-HKM Cotonou. Rev Afr Urol Androl. 2 juill 2015; 1 (4): 193-6. |
| [4] | Xylinas E, Peyromaure M. Cancer de la prostate: traitements. In: EMC- Cancérologie. Paris: Elsevier Masson; 2020. p. 1-19. |
| [5] | Fizazi K, Irani J, Arfi-Rouche J, Chapet O. Tumeurs de la prostate. In: Collège National des Enseignants en Cancérologie. 2ème. Paris: MED-LINE; 2019. p. 349-71. |
| [6] | Yahaya J, Okecha T, Odida M, Wabinga H. Prognostic Factors for Overall Survival of Patients with Prostate Cancer in Kyadondo County, Uganda. Prostate Cancer. 27 janv 2020; 2020 (1): 1-9. |
| [7] | Mbey PM, Mukuku O, Arung WK, Tengu GK, Amisi NL, Kyabu VK, et al. Clinical, Histopathological, and Prognostic Characteristics of Patients with Prostate Cancer in Lubumbashi, Democratic Republic of Congo. Prostate Cancer. 10 déc 2020; 2020: e5286929. |
| [8] | Fournier G, Valeri A, Mangin P, Cussenot O. Cancer de la prostate. Épidémiologie. Facteurs de risques. Anatomopathologie. In: EMC- Cancérologie. Elsevier Masson; 2020. p. 1-13. |
| [9] | Cussenot O, Teillac P. Le cancer de la prostate. Paris: John Libbey Eurotext; 2000. 156 p. (Pathologie, sciences, formation). |
| [10] | François T, Alezra É, Kikassa JC, Saint F, Raynal G. Le dépistage du cancer de la prostate vu par les médecins généralistes. Prog En Urol. 2013; 23 (16): 1407-11. |
| [11] | Rozet F, Mongiat-Artus P, Hennequin C, Beauval JB, Beuzeboc P, Cormier L, et al. Recommandations françaises du Comité de cancérologie de l’AFU – actualisation 2020–2022 : cancer de la prostate. Prog En Urol. nov 2020; 30 (12S): S136-251. |
| [12] | Kirakoya B, Hounnasso PP, Pare AK, Mustapha AB, Zango B. Clinico-pathological features of prostate cancer at the university hospital Yalgado Ouedraogo, Ouagadougou, Burkina Faso. J West Afr Coll Surg. déc 2014; 4 (4): 70-81. |
| [13] | Engbang JPN, Sala B, Moby H, Ligan Y, Djimeli BD, Simo G, et al. Epidemiomorphology of Prostate Cancer in Cameroon: About 1047 Cases. J Cancer Tumor Int. 25 nov 2017; 6 (3): 1-8. |
| [14] | Richard TS, Ahmadou M, Hervé NKA, Faustin SEP, Myriam BE, Franklin DS, et al. Prostate Cancer Characteristics and Associated Factors in Northern Cameroon. J Cancer Ther. 12 mai 2021; 12 (5): 289-301. |
| [15] | Cassell A, Yunusa B, Jalloh M, Ndoye M, Mbodji M, Diallo A, et al. Management of Advanced and Metastatic Prostate Cancer: A Need for a Sub-Saharan Guideline. J Oncol. 5 déc 2019; 2019 (2): 1-10. |
| [16] | Mahal BA, Butler S, Franco I, Spratt DE, Rebbeck TR, D’Amico AV, et al. Use of Active Surveillance or Watchful Waiting for Low-Risk Prostate Cancer and Management Trends Across Risk Groups in the United States, 2010-2015. JAMA. 19 févr 2019; 321 (7): 704-6. |
| [17] | Rugwizangoga B, Vuhahula E, Kitinya J. A Combination Of Ki67 Expression And Gleason Score For Prostatic Adenocarcinoma Offers Better Prognostic Information Than Either Alone. Internet J Urol. 5 févr 2014; 12 (1): 1-9. |
| [18] | Xu L, Wang J, Guo B, Zhang H, Wang K, Wang D, et al. Comparison of clinical and survival characteristics between prostate cancer patients of PSA-based screening and clinical diagnosis in China. Oncotarget. 2 janv 2018; 9 (1): 428-41. |
APA Style
Hierrhum Aboubacar, B., Nina Assanatou Jumelle, Z., Valérie, O., Epala Brice Aymard, N., Malanda Judith, N., et al. (2023). Prognostic Factors for Prostate Cancer at the Brazzaville University Hospital Center. International Journal of Clinical Oncology and Cancer Research, 8(4), 94-100. https://doi.org/10.11648/j.ijcocr.20230804.13
ACS Style
Hierrhum Aboubacar, B.; Nina Assanatou Jumelle, Z.; Valérie, O.; Epala Brice Aymard, N.; Malanda Judith, N., et al. Prognostic Factors for Prostate Cancer at the Brazzaville University Hospital Center. Int. J. Clin. Oncol. Cancer Res. 2023, 8(4), 94-100. doi: 10.11648/j.ijcocr.20230804.13
AMA Style
Hierrhum Aboubacar B, Nina Assanatou Jumelle Z, Valérie O, Epala Brice Aymard N, Malanda Judith N, et al. Prognostic Factors for Prostate Cancer at the Brazzaville University Hospital Center. Int J Clin Oncol Cancer Res. 2023;8(4):94-100. doi: 10.11648/j.ijcocr.20230804.13
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ijcocr.20230804.13,
author = {Bambara Hierrhum Aboubacar and Zerbo Nina Assanatou Jumelle and Odero-Marah Valérie and Nkoua Epala Brice Aymard and Nsonde Malanda Judith and Nkoua-Mbon Jean-Bernard},
title = {Prognostic Factors for Prostate Cancer at the Brazzaville University Hospital Center},
journal = {International Journal of Clinical Oncology and Cancer Research},
volume = {8},
number = {4},
pages = {94-100},
doi = {10.11648/j.ijcocr.20230804.13},
url = {https://doi.org/10.11648/j.ijcocr.20230804.13},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijcocr.20230804.13},
abstract = {Second cancer frequently diagnosed in men; prostate cancer is responsible for high mortality. His prognosis has benefited from significant technical improvements. Determining prognostic factors in prostate cancer is an integral part of the therapeutic decision-making process. The aim of this study was to determine the prognostic factors of prostate cancer in the cancer department of University Hospital of Brazzaville in Congo. This was a retrospective descriptive study, which took place from 1 January 2016 to 31 December 2020, in the cancer department of the University Hospital of Brazzaville in Congo. During the study period, 118 files were retained. The survival curves were realized according to the Kaplan-Meier model, and the statistical comparison according to the Log-Rank model. The significance threshold was set at 5%. The results found that mean age was 68 ± 7.74 years. Low urinary tract symptoms accounted for 68.64% of the discovery circumstances. The Initial PSA was greater than 100 ng/ml in 65.25% of patients. Metastases were found in 95.76% of patients. Overall survival at 3 years was 15%. Survival differed significantly by age (p = 0.0017); WHO performance status (p = 0.0000); clinical stage (p = 0.0000) and metastatic site (p = 0.0022). Finally, the incidence of prostate cancer is increasing worldwide, hence the interest of defining a screening strategy, allowing to institute management with better results.
},
year = {2023}
}
TY - JOUR T1 - Prognostic Factors for Prostate Cancer at the Brazzaville University Hospital Center AU - Bambara Hierrhum Aboubacar AU - Zerbo Nina Assanatou Jumelle AU - Odero-Marah Valérie AU - Nkoua Epala Brice Aymard AU - Nsonde Malanda Judith AU - Nkoua-Mbon Jean-Bernard Y1 - 2023/12/06 PY - 2023 N1 - https://doi.org/10.11648/j.ijcocr.20230804.13 DO - 10.11648/j.ijcocr.20230804.13 T2 - International Journal of Clinical Oncology and Cancer Research JF - International Journal of Clinical Oncology and Cancer Research JO - International Journal of Clinical Oncology and Cancer Research SP - 94 EP - 100 PB - Science Publishing Group SN - 2578-9511 UR - https://doi.org/10.11648/j.ijcocr.20230804.13 AB - Second cancer frequently diagnosed in men; prostate cancer is responsible for high mortality. His prognosis has benefited from significant technical improvements. Determining prognostic factors in prostate cancer is an integral part of the therapeutic decision-making process. The aim of this study was to determine the prognostic factors of prostate cancer in the cancer department of University Hospital of Brazzaville in Congo. This was a retrospective descriptive study, which took place from 1 January 2016 to 31 December 2020, in the cancer department of the University Hospital of Brazzaville in Congo. During the study period, 118 files were retained. The survival curves were realized according to the Kaplan-Meier model, and the statistical comparison according to the Log-Rank model. The significance threshold was set at 5%. The results found that mean age was 68 ± 7.74 years. Low urinary tract symptoms accounted for 68.64% of the discovery circumstances. The Initial PSA was greater than 100 ng/ml in 65.25% of patients. Metastases were found in 95.76% of patients. Overall survival at 3 years was 15%. Survival differed significantly by age (p = 0.0017); WHO performance status (p = 0.0000); clinical stage (p = 0.0000) and metastatic site (p = 0.0022). Finally, the incidence of prostate cancer is increasing worldwide, hence the interest of defining a screening strategy, allowing to institute management with better results. VL - 8 IS - 4 ER -
Clinical Hematology Oncology Department, University Teaching Hospital Bogodogo, Ouagadougou, Burkina Faso; Health Sciences Training and Research Unit Department (UFR/SDS), Joseph KI-ZERBO University, Ouagadougou, Burkina Faso
